Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 873,330
  • Shares Outstanding, K 396,968
  • Annual Sales, $ 164,070 K
  • Annual Income, $ -372,180 K
  • EBIT $ -407 M
  • EBITDA $ -374 M
  • 60-Month Beta 0.83
  • Price/Sales 5.35
  • Price/Cash Flow N/A
  • Price/Book 1.25

Options Overview Details

View History
  • Implied Volatility 269.13% (-219.99%)
  • Historical Volatility 104.77%
  • IV Percentile 78%
  • IV Rank 19.20%
  • IV High 1,223.10% on 07/21/25
  • IV Low 42.44% on 06/25/25
  • Expected Move (DTE 7) 0.27 (12.48%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 751
  • Volume Avg (30-Day) 6,624
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 258,654
  • Open Int (30-Day) 267,033
  • Expected Range 1.91 to 2.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.22
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.25
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.08 +6.01%
on 11/07/25
2.74 -19.53%
on 11/11/25
+0.39 (+21.82%)
since 11/05/25
3-Month
1.76 +25.28%
on 11/05/25
2.74 -19.53%
on 11/11/25
-0.29 (-11.45%)
since 09/05/25
52-Week
1.64 +34.57%
on 05/19/25
9.30 -76.29%
on 12/09/24
-6.27 (-73.97%)
since 12/05/24

Most Recent Stories

More News
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering...

IOVA : 2.20 (-0.23%)
Iovance Biotherapeutics: Q3 Earnings Snapshot

Iovance Biotherapeutics: Q3 Earnings Snapshot

IOVA : 2.20 (-0.23%)
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

Quarterly Revenue Growth of 13% to ~$68 Million  Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class Clinical Profile for Lifileucel in Previously Treated...

IOVA : 2.20 (-0.23%)
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

26% Objective Response Rate  Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN...

IOVA : 2.20 (-0.23%)
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END

IOVA : 2.20 (-0.23%)
MRK : 100.28 (-0.60%)
JNJ : 202.06 (-0.21%)
LLY : 1,014.21 (-0.03%)
OTLC : 0.0938 (+1.41%)
Targeted Cell Therapies and Precision Degraders Drive $404B Cancer Market Expansion

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists engineered invisible immune cells in October 2025 that hide from rejection while destroying tumors[1],...

IOVA : 2.20 (-0.23%)
GMAB : 31.72 (-0.94%)
NRIX : 17.93 (-0.50%)
GTBP : 0.6000 (-4.73%)
SLS : 1.7100 (-1.72%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering...

IOVA : 2.20 (-0.23%)
Healthcare's Convergence Accelerates as Aging Demographics Meet Breakthrough Therapies

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – America's chronic disease burden has reached $4.9 trillion in annual healthcare expenditures, driven by...

VKTX : 38.62 (+0.13%)
LXRX : 1.3900 (-2.11%)
IOVA : 2.20 (-0.23%)
AVAI : 0.2997 (+1.56%)
TNYA : 1.3700 (-0.72%)
CI : 267.74 (-0.25%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering...

IOVA : 2.20 (-0.23%)
Advancing Cancer Research Brings New Hope for Patients Worldwide

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END

IOVA : 2.20 (-0.23%)
AZN : 90.43 (+0.44%)
MRK : 100.28 (-0.60%)
OTLC : 0.0938 (+1.41%)
BMY : 52.35 (+0.77%)

Business Summary

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own...

See More

Key Turning Points

3rd Resistance Point 2.32
2nd Resistance Point 2.28
1st Resistance Point 2.24
Last Price 2.20
1st Support Level 2.16
2nd Support Level 2.12
3rd Support Level 2.08

See More

52-Week High 9.30
Fibonacci 61.8% 6.37
Fibonacci 50% 5.47
Fibonacci 38.2% 4.57
Last Price 2.20
52-Week Low 1.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar